
LAQUINIMOD: A NEW ORAL IMMUNOMODULATOR FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
New Players in MS
October 30, 2010
Infos
Congress: | The 4th World Congress on Controversies in Neurology (CONy) |
---|---|
Presenter: | P. Vermersch |
Description: | Laquinimod is a novel oral, once-daily immunomodulator which is currently in advanced stages of clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS). Laquinimod was demonstrated to be effective in various experimental autoimmune encephalomyelitis models. The ameliorating activity of laquinimod is mediated by various effects, modulating the immune system away from its typical disease properties. These include effects seen on cytokine profile, leukocytes infiltration to inflamed tissues and antigen presentation. Neuroprotective effects were demonstrated by reduced spinal cord demyelination and axonal loss in MS animal models.
|
Category: | Inflammation; Cytokines; Neurology; Multiple Sclerosis; treatment; |